/PRNewswire/ Alume Biosciences, Inc. has secured $13 million in Series B financing to advance its lead candidate, Bevonescein (ALM-488), in Phase 3 clinical.
/PRNewswire/ Alume Biosciences, Inc. has secured $13 million in Series B financing to advance its lead candidate, Bevonescein (ALM-488), in Phase 3 clinical.
/PRNewswire/ Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, announced today that it has been awarded a $3.4M.
/PRNewswire/ Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, announced today that it has been awarded a $3.4M.
Alume Receives Commercialization Readiness Program Grant from the NIH to Support Commercialization of ALM-488 to Highlight Nerves streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.